Amir Avan
Impact in
- Cancer Research top 10%
- MicroRNA in disease regulation
- Cancer-related molecular mechanisms research
Papers in
-
- RNA modifications and cancer 5
-
- Cancer, Lipids, and Metabolism 6
- Cancer-related molecular mechanisms research 5
- MicroRNA in disease regulation 4
- Co-authors
- Gordon A. Ferns (58 shared papers)Majid Khazaei (43 shared papers)Seyed Mahdi Hassanian (43 shared papers)Hamed Mirzaei (1 shared paper)Elham Nazari (16 shared papers)Fereshteh Asgharzadeh (12 shared papers)Majid Ghayour‐Mobarhan (18 shared papers)Hamed Tabesh (4 shared papers)
- Journals
- Current Pharmaceutical Design (11 papers)Current Cancer Drug Targets (4 papers)Gene (3 papers)Journal of Clinical Laboratory Analysis (3 papers)Current Drug Targets (3 papers)
- Partner nations
- IranUnited KingdomAustralia
In The Last Decade
Amir Avan
76 papers receiving 932 citations
Peers
Comparison fields: 5 of 90
- Cancer Research 173
- Oncology 148
- Molecular Biology 312
- Biomaterials 58
- Immunology 78
Countries citing papers authored by Amir Avan
This map shows the geographic impact of Amir Avan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Amir Avan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Amir Avan more than expected).
Fields of papers citing papers by Amir Avan
This network shows the impact of papers produced by Amir Avan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Amir Avan. The network helps show where Amir Avan may publish in the future.
Co-authors
The 25 scholars most cited alongside Amir Avan, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 80 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2017 | 85 | |
| 2 | 2021 | 65 | |
| 3 | 2015 | 46 | |
| 4 | 2022 | 39 | |
| 5 | 2015 | 33 | |
| 6 | 2023 | 30 | |
| 7 | 2023 | 29 | |
| 8 | 2020 | 28 | |
| 9 | 2016 | 28 | |
| 10 | 2019 | 25 | |
| 11 | 2021 | 24 | |
| 12 | 2018 | 23 | |
| 13 | 2016 | 23 | |
| 14 | 2020 | 21 | |
| 15 | 2022 | 21 | |
| 16 | 2022 | 21 | |
| 17 | 2021 | 20 | |
| 18 | 2022 | 19 | |
| 19 | 2017 | 19 | |
| 20 | 2023 | 17 |
About Amir Avan
Amir Avan is a scholar working on Molecular Biology, Cancer Research, Oncology, Cardiology and Cardiovascular Medicine and Endocrinology, Diabetes and Metabolism, having authored 80 papers that have together received 945 indexed citations. Recurring topics across this work include Cancer Cells and Metastasis (6 papers), Lipid metabolism and disorders (6 papers), Cancer, Lipids, and Metabolism (6 papers), Cancer-related molecular mechanisms research (5 papers), RNA modifications and cancer (5 papers), MicroRNA in disease regulation (4 papers), Renin-Angiotensin System Studies (3 papers) and Diabetes, Cardiovascular Risks, and Lipoproteins (3 papers). The work is most often cited by research in Cancer Research (173 citations), Oncology (148 citations), Molecular Biology (312 citations), Biomaterials (58 citations) and Immunology (78 citations). Amir Avan has collaborated with scholars based in Iran, United Kingdom and Australia. Frequent co-authors include Gordon A. Ferns, Majid Khazaei, Seyed Mahdi Hassanian, Hamed Mirzaei, Elham Nazari, Fereshteh Asgharzadeh, Majid Ghayour‐Mobarhan, Hamed Tabesh, Seyed Reza Mirhafez and Alireza Hashemzadeh. Their work appears in journals such as Current Pharmaceutical Design, Current Cancer Drug Targets, Gene, Journal of Clinical Laboratory Analysis and Current Drug Targets.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.